C-Mos: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
'''c-Mos''' is a proto-oncogene. Oocyte maturation factor. It's involved in the [[MAPK]]- [[signaling pathway]]. | '''c-Mos''' is a proto-oncogene. Oocyte maturation factor. It's involved in the [[MAPK]]- [[signaling pathway]]. | ||
Line 6: | Line 6: | ||
[[Image:signal transduction pathways.jpg|300px|thumb|right|Overview of signal transduction pathways]] | [[Image:signal transduction pathways.jpg|300px|thumb|right|Overview of signal transduction pathways]] | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 23:15, 8 August 2012
WikiDoc Resources for C-Mos |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on C-Mos at Clinical Trials.gov Clinical Trials on C-Mos at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on C-Mos
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating C-Mos Risk calculators and risk factors for C-Mos
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
c-Mos is a proto-oncogene. Oocyte maturation factor. It's involved in the MAPK- signaling pathway.